LBRX
LB PHARMACEUTICALS INC
Last earnings -4.8% on 2026-05-12
$31.92
▲ +2.97%$31.92▲ +84.51%
over 1Y
L $14.61EODHDH $32.88
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.0%
1W+6.9%
1M+14.8%
3M+33.9%
YTD+56.2%
1Y+84.5%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 12 analysts
Buy
Pre-revenue single-asset clinical-stage biotech freshly IPO'd in Sept 2025 — binary LB-102 outcome, not investable as a stock pick.
LB Pharmaceuticals is a clinical-stage biotech whose entire enterprise value rides on a single asset, LB-102, for which the 10-K explicitly flags uncertain 'timing, progress, potential registrational quality, and results' of trials, plus 'ability to obtain funding' to complete development. The company has no commercial revenue (FY2025 revenue is blank in the data), generated a -$25.2M net loss with -$35.2M of operating cash burn, and IPO'd on Nasdaq on September 11, 2025 — which explains the +988% jump in cash to $250M and the +833% jump in total assets. Everything on the balance sheet is IPO proceeds, not operating progress.
Financials · annual, by fiscal year
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | — | — |
| Net income | -$63.1M | -$25.2M |
| Diluted EPS | -$176.15 | -$3.13 |
| Net margin | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$665M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.8%
FCF yield-3.9%
Quality & risk
ROIC (est.)—
Free cash flow-$35.3M
Total debt—
Net cash$250M
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Officer / director change2026-06-10
Executive/director change disclosed with exhibits; routine governance update
- 8-K Shareholder vote2026-06-09
Annual meeting voting results filed; shareholder proposals decided
- 8-K Earnings results2026-05-12
Q1 2026 10-Q: cash runway intact, LB-102 clinical spend ongoing, no revenue
- 10-Q Quarterly report2026-05-12
Q1 2026 10-Q: cash runway intact, LB-102 clinical spend ongoing, no revenue
- DEF 14A Proxy statement2026-04-23
Annual proxy filed; director slate and routine governance items for vote
- S-1 Securities registration2026-04-06
S-1 registration filed post-IPO; likely resale shelf — potential supply overhang
- 8-K Earnings results2026-03-26
FY2025 10-K: $250M cash, loss narrowed to $25M, LB-102 schizophrenia program advancing
- 10-K Annual report2026-03-26
FY2025 10-K: $250M cash, loss narrowed to $25M, LB-102 schizophrenia program advancing
- 8-K Officer / director change2026-03-16
Executive officer/director change disclosed; leadership transition
Recent filings
all on EDGAR ↗424B3Filing2026-06-10open ↗8-KPeriod ending 2026-06-082026-06-10open ↗144Filing2026-06-09open ↗424B3Filing2026-06-09open ↗8-KPeriod ending 2026-06-032026-06-09open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗
Frequently asked
- Is LB PHARMACEUTICALS INC (LBRX) a buy?
- LBRX currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Pre-revenue single-asset clinical-stage biotech freshly IPO'd in Sept 2025 — binary LB-102 outcome, not investable as a stock pick.
- What is LB PHARMACEUTICALS INC's quality score?
- LBRX scores 59.87179487179487/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001691082, latest 10-Q filed 2026-05-12) · EODHD · analysis by claude-code · as of 6/25/2026, 2:42:54 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.